A Bayesian adaptive design for two-stage clinical trials with survival data

Department of Statistics, University of Calcutta, 35 Ballygunge Circular Road, Kolkata 700 019, India.
Lifetime Data Analysis (Impact Factor: 0.65). 11/2009; 15(4):468-92. DOI: 10.1007/s10985-009-9134-4
Source: PubMed


A randomized two-stage adaptive Bayesian design is proposed and studied for allocation and comparison in a phase III clinical trial with survival time as treatment response. Several exact and limiting properties of the design and the follow-up inference are studied, both numerically and theoretically, and are compared with a single-stage randomized procedure. The applicability of the proposed methodology is illustrated by using some real data.

1 Follower
36 Reads

  • Statistics in Medicine 03/2006; 25(6):933-41. DOI:10.1002/sim.2252 · 1.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Statistical sciences have recently made advancements that allow improved precision or reduced sample size in clinical research studies. Herein, we review 4 of the more promising: (1) improvements in approaches for dose selection trials, (2) approaches for sample size adjustment, (3) selection of study end point and associated statistical methods, and (4) frequentist versus Bayesian statistical methods. Whereas each of these holds the opportunity for more efficient trials, each are associated with the need for more stringent assumptions or increased complexity in the interpretation of results. The opportunities for these promising approaches, and their associated "costs," are reviewed.
    Stroke 03/2007; 38(2 Suppl):804-8. DOI:10.1161/01.STR.0000252679.07927.e5 · 5.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Flexible trials with adaptive design modification at interim analyses have been recently proposed as an answer to cope with some limitations of traditional designs for phase III trials. Actually, the sample size and duration of fixed design trials strongly depend on the determination, prior to the study, of key parameters such as the expected treatment effect and the event rates. A misspecification of these parameters may result in an underpowered or overpowered trial. In the flexible framework, the remainder of a design can be modified at an interim analysis, while preserving the initially specified global error rates. In this work, we present a flexible design with sample size re-evaluation for survival trials and study its properties in practical settings. The results show that, if parameters are initially misspecified, the proposed method allows an improved power control with a reasonable increase in sample size, if any. Practical guidelines concerning the choice of the trial parameters are also given.
    Statistics in Medicine 11/2007; 26(27):5002-13. DOI:10.1002/sim.2966 · 1.83 Impact Factor
Show more

Similar Publications